Respimat® Inhaler

DEVICE2 trials

Sponsors

Boehringer Ingelheim

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 2

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

CompletedNCT00696020

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2008-06-30Updated: 2015-08-13

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00720499

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2008-07-31Updated: 2015-08-17

Related Papers

Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients.

2019-10-2519 citations

Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD.

2019-03-067 citations

Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease

Advances in Therapy2015-09-0116 citations